Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
UCSF Helen Diller Family Comprehensive Cancer Center · University of California, San Francisco · +11 more institutions
Indexed incrossrefpubmed
Abstract
PURPOSE: In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P
Citation impact
441
total citations
- FWCI
- 35.40
- Percentile
- 100%
- References
- 19
Citations per year
Authors
15- HSHope S. RugoCorresponding
UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
- RSRichard S. Finn
University of California, Los Angeles
- VDVéronique Dièras
Centre Eugène Marquis, Institut Curie
- JEJohannes Ettl
Technical University of Munich, Klinikum rechts der Isar
- OLOleg Lipatov
Republican Oncological Clinical Dispensary
Topics & keywords
Topics
Keywords
- Palbociclib
- Letrozole
- Medicine
- Breast cancer
- Oncology
- Internal medicine
- Placebo
- Metastatic breast cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.